We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$671M
AUM Growth
-$749M
Cap. Flow
-$596M
Cap. Flow %
-88.74%
Top 10 Hldgs %
41.79%
Holding
248
New
39
Increased
16
Reduced
53
Closed
62

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$11.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$7.64M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.48M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.45M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.08M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$13.7M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.89M
3
CMPS
Compass Pathways
CMPS
+$6.85M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.93M
5
BCAB icon
BioAtla
BCAB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 50.73%
2 Consumer Staples 0.3%
3 Technology 0.3%
4 Financials 0.11%
5 Real Estate 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
151
EyePoint Inc
EYPT
$1.01B
$262K 0.04%
21,427
-15,000
-41% -$202K
ATYR
152
aTyr Pharma
ATYR
$47.1M
$262K 0.04%
35,048
-527,198
-94% -$4.4M
GNCA
153
DELISTED
Genocea Biosciences, Inc.
GNCA
$228K 0.03%
196,821
– –
CMPX icon
154
Compass Therapeutics
CMPX
$342M
$222K 0.03%
+70,000
New +$232K
ALNY icon
155
Alnylam Pharmaceuticals
ALNY
$27.3B
$204K 0.03%
1,195
-266
-18% -$49.4K
ARNA
156
DELISTED
Arena Pharmaceuticals Inc
ARNA
$200K 0.03%
+2,161
New +$142K
IVA
157
Inventiva
IVA
$1.05B
$197K 0.03%
14,748
– –
ORTX
158
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$195K 0.03%
14,813
– –
SAGE
159
CALL
DELISTED
Sage Therapeutics
SAGE
$192K 0.03%
+4,500
New +$188K
OCUL icon
160
Ocular Therapeutix
OCUL
$1.81B
$191K 0.03%
27,551
-250,000
-90% -$1.94M
MRTX
161
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$191K 0.03%
1,300
– –
ASLN
162
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$187K 0.03%
22,934
-12,500
-35% -$749K
NVAX icon
163
Novavax
NVAX
$1.2B
$183K 0.03%
1,283
– –
ACRS icon
164
Aclaris Therapeutics
ACRS
$732M
$156K 0.02%
10,785
-31,927
-75% -$484K
PBYI icon
165
Puma Biotechnology
PBYI
$401M
$152K 0.02%
49,843
– –
DFTX
166
Definium Therapeutics
DFTX
$5.82B
$138K 0.02%
+6,667
New +$213K
APTO
167
DELISTED
Aptose Biosciences, Inc.
APTO
$138K 0.02%
227
– –
BTAI icon
168
BioXcel Therapeutics
BTAI
$24.7M
$104K 0.02%
+323
New +$139K
ATNX
169
DELISTED
Athenex, Inc. Common Stock
ATNX
$103K 0.02%
3,807
– –
GMDA
170
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$79K 0.01%
31,029
– –
AMYT
171
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$72K 0.01%
34,131
– –
TNGX icon
172
Tango Therapeutics
TNGX
$4.43B
$56K 0.01%
+5,180
New +$62.3K
SLNO
173
DELISTED
Soleno Therapeutics
SLNO
$50K 0.01%
8,113
– –
IGMS
174
DELISTED
IGM Biosciences
IGMS
$44K 0.01%
1,500
-50,000
-97% -$2.48M
ACAD icon
175
Acadia Pharmaceuticals
ACAD
$4.42B
$42K 0.01%
1,765
-280,000
-99% -$5.63M
5 6
7
8 9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Ikarian Capital held 248 positions worth $671M, down 53% from $1.42B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital withdrew a net $596M in Q4 2021, closing 62 positions and reducing 53 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 30% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Kezar Life Sciences worth $17.1M.

  • Ikarian Capital's largest Q4 2021 buy was Kezar Life Sciences: 102,092 shares worth $17.1M.
  • Ikarian Capital added most to Zentalis Pharmaceuticals in Q4 2021, an estimated $7.64M increase.
  • Ikarian Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $5.93M.
  • Ikarian Capital fully exited Apellis Pharmaceuticals in Q4 2021, selling an estimated $13.7M.
  • Ikarian Capital's ten largest holdings make up 42% of its $671M portfolio in Q4 2021.
  • Ikarian Capital opened 39 new positions and closed 62 in Q4 2021.
  • Ikarian Capital's portfolio value fell 53% quarter-over-quarter to $671M.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.